The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
Micaela Laber, MPH, MBA
Advertisement
Articles by Micaela Laber, MPH, MBA
Advertisement
Latest Updated Articles
- Humira: The First $20 Billion Drug
February 8th 2023
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies
5